Xponance’s Vanda Pharmaceuticals VNDA Stock Holding History

Xponance’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-16,427	Closed	-$71K	–	1288
2023 Q3	$71K	Sell	16,427 -1,392	-8%	-$7.73K	﹤0.01%	1184
2023 Q2	$117K	Buy	+17,819	New	+$114K	﹤0.01%	1184

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Xponance's VNDA Position: Q4 2023 in Review

Xponance sold out of Vanda Pharmaceuticals (VNDA) in Q4 2023, closing a stake of 16,427 shares — an estimated $71K sold.

Xponance first reported a position in VNDA in Q2 2023 and held it in 2 quarters. The position peaked at $117K in Q2 2023. 157 funds tracked by Wall St. Rank hold VNDA as of Q4 2023.

Xponance reported no remaining Vanda Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Xponance sold 16,427 Vanda Pharmaceuticals shares in Q4 2023, an estimated $71K.
Xponance first reported a position in Vanda Pharmaceuticals in Q2 2023 and held it in 2 quarters.
Xponance's Vanda Pharmaceuticals position peaked at $117K in Q2 2023.
157 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2023.

Based on Xponance's 13F filing for Q4 2023, filed 31 Jan 2024.